The Effects of Ranitidine Treatment on the Risk of Necrotizing Enterocolitis in Preterm Infants

Zlatan Zvizdic, Emir Milisic, Asmir Jonuzi, Sabina Terzic, Denisa Zvizdic, Semir Vranic

The Effects of Ranitidine Treatment on the Risk of Necrotizing Enterocolitis in Preterm Infants

Číslo: 1/2021
Periodikum: Acta Medica
DOI: 10.14712/18059694.2021.2

Klíčová slova: ranitidine, necrotizing enterocolitis, preterm infants, developing countries

Pro získání musíte mít účet v Citace PRO.

Přečíst po přihlášení

Anotace: Introduction: Gastric acidity plays an important role in the protection of infants against various pathogens from the environment. The histamine-2 receptor blockers (H2-blockers) are off-labeled drugs that are frequently prescribed in preterm neonates to prevent stress ulcers. The impact of the H2-blockers on the development of the necrotizing enterocolitis (NEC) in preterm infants is still controversial, particularly in the developing world. Materials and Methods: One hundred twenty-two preterm infants were enrolled in the study. The multivariate logistic regression model was used to identify potential postnatal risk factors associated with NEC. Results: Preterm infants (n = 51) with total NEC, medical NEC, and surgical NEC had the highest rate of receiving ranitidine compared with controls (n = 71) (39.2%, 19.6%, and 47.6%, p < 0.05). Logistic regression analysis revealed that ranitidine use and nosocomial infections were significantly associated with NEC development (odds ratios 1.55 and 3.3). Conclusions: We confirm that ranitidine administration was associated with an increased risk of NEC in preterm infants. H2-blockers use should be only administered in very strictly selected cases after careful consideration of the risk-benefit ratio.